Canadian biotechnology company Zymeworks Inc. has announced a definitive agreement to acquire Theravance Biopharma in an all-cash transaction worth approximately $929 million. The acquisition represents a major strategic move for Zymeworks, enabling the company to diversify beyond its oncology-focused portfolio and establish a stronger presence in the respiratory medicine market.
The transaction is expected to strengthen Zymeworks’ commercial business while providing access to a revenue-generating respiratory therapy already approved by the U.S. Food and Drug Administration (FDA).
Deal Overview
Under the terms of the agreement:
- Transaction Value: Approximately $929 million
- Deal Type: All-cash acquisition
- Offer Price: $17.00 per share in cash to Theravance shareholders
- Additional Benefit: Shareholders will also receive a Contingent Value Right (CVR)
The CVR will entitle shareholders to receive 80% of the net proceeds generated from any future licensing, sale, divestiture, or monetization of ampreloxetine over the next 10 years.
Why This Acquisition Matters
The acquisition significantly expands Zymeworks’ business beyond oncology by adding a commercial respiratory product to its portfolio.
The biggest asset included in the acquisition is:
YUPELRI® (Revefenacin)
YUPELRI® is an FDA-approved, once-daily nebulized treatment indicated for patients with Chronic Obstructive Pulmonary Disease (COPD).
The product currently generates approximately:
- $60 million in annualized cash flow
- Revenue through U.S. profit-sharing
- Additional income from international royalty agreements
For Zymeworks, this provides an immediate commercial revenue stream while reducing dependence on oncology-focused development programs.
What Led to the Acquisition?
Earlier this year, Theravance Biopharma initiated a strategic review after disappointing clinical trial results.
The company’s late-stage CYPRESS Phase III trial evaluating ampreloxetine failed to meet its primary endpoint.
Following the setback, Theravance:
- Implemented cost-reduction initiatives
- Reviewed strategic alternatives
- Explored opportunities to maximize shareholder value
These efforts ultimately resulted in the acquisition agreement with Zymeworks.
Regulatory and Shareholder Approval
The boards of directors of both companies have unanimously approved the transaction.
The acquisition is expected to close during the second half of 2026, subject to:
- Shareholder approval
- Regulatory clearances
- Customary closing conditions
Strategic Benefits for Zymeworks
The acquisition offers several strategic advantages:
- Expansion beyond oncology into respiratory medicine
- Addition of an FDA-approved commercial product
- Immediate recurring cash flow
- Diversified revenue sources
- Enhanced long-term growth opportunities
- Potential future value from ampreloxetine through the CVR structure
The company also expects the transaction to be accretive to both earnings and cash flow after completion.
Impact on the Biotechnology Industry
The deal highlights a growing trend in the biotechnology sector, where companies are increasingly acquiring commercial-stage assets to strengthen financial stability and reduce dependence on experimental drug pipelines.
For Zymeworks, the acquisition provides both a marketed respiratory therapy and an opportunity to broaden its therapeutic focus, positioning the company for more balanced long-term growth.
Key Highlights
- Acquirer: Zymeworks Inc.
- Target Company: Theravance Biopharma
- Transaction Value: Approximately $929 million
- Offer Price: $17 per share (cash)
- Additional Consideration: CVR covering 80% of future ampreloxetine proceeds
- Key Commercial Asset: YUPELRI® (revefenacin)
- Therapeutic Area: Chronic Obstructive Pulmonary Disease (COPD)
- Annualized Cash Flow from YUPELRI®: Approximately $60 million
- Expected Closing: Second half of 2026 (subject to approvals)
Conclusion
Zymeworks’ planned $929 million acquisition of Theravance Biopharma marks a significant milestone in the company’s evolution from an oncology-focused biotechnology firm to a more diversified biopharmaceutical company. By adding the commercially successful YUPELRI® respiratory treatment and creating potential future value through the CVR linked to ampreloxetine, Zymeworks aims to strengthen its revenue base and accelerate long-term growth. If completed as expected in the second half of 2026, the acquisition could reshape the company’s commercial strategy and enhance its position in the global biopharmaceutical market.
Recommended Products
